DE&I

Truly moving the needle in clinical trial diversity comes down to embracing two fundamental pieces of the DE&I puzzle.

Tola Olorunnisola, senior vice president – general manager, clinical services and strategy, at Avantor, discusses the progress and challenges in incorporating more diversity-driven measures in drug development.

The six steps to designing a successful diversity action plan for a clinical trial protocol.

Why weighing all of the ‘DE&I’ components is critical at site and sponsor levels.

Gadi Saarony, CEO of Advarra discusses the current state of diversity in clinical trials and how industry needs to be more proactive in addressing it.

A study exploring healthcare preference and experience in this population group uncovers new insights and opportunities related to clinical research participation.

With significant race and sex disparities in the area of peripheral artery disease, a study shows that clinical trials often lack representative patient populations.

It is crucial throughout the clinical trials space to understand the challenges and triumphs of DEI.

Despite repeated calls from the FDA, patient advocates, and scholars for the need to address demographic disparities in clinical research, White participants still remain overrepresented while racial minority participants remain underrepresented in clinical trials.

Leveraging a “diversity by design” approach can build patient narratives and optimize protocols from the onset.

Robust data sets which can effectively represent diverse populations are key to driving greater inclusivity in trials.

Expanding clinical trial access to include historically underrepresented ethnic and racial minorities means addressing root-cause barriers, including taxation.

Authors in this area focused on increasing diversity in clinical trials through patient-first payment options and trial design.

Despite regulatory guidance, disability status is frequently unreported or overlooked in trial design.

Patient-first trial design, based around the tenets of adaptability and personalization, has emerged as a key solution to increase diversity and improve trial outcomes for all.

Amid CVS’ surprise exit from the clinical research space and the ensuing broader questions, study investigates the benefits of pharmacy chain involvement—along with the concerns and barriers to adoption.

If a future Supreme Court ruling on diversity were to be applicable to clinical research, the FDA’s positions on diversity will take on even more importance.

Developing consensus answers to these questions can aid industry in avoiding duplicative efforts and implementing new ideas more efficiently.

Differing levels of trust in clinical trials information channels across diverse populations is examined in this research.

In this Q&A, Ashley Moultrie, director of diversity, equity, and inclusion and community engagement for Javara shares her thoughts on current progress and remaining roadblocks in employing effective DEI strategies in clinical research.

Harsha K. Rajasimha, PhD, founder and executive chairman, IndoUSrare, provides the OCT audience insights into better achieving DEIA clinical trials.

In this Q&A, Santuccione Chadha speaks on the lack of sex- and gender-based analysis in clinical trial results.

Through grassroots patient education, local pharmacies serve as a pivotal doorway to improving access to trials.

Improving clinical trial diversity and health equity through strategic collaborations.

Tufts CSDD study finds that acts of microaggression negatively impact psychological safety and performance.

Amidst difficulty in attracting underrepresented populations, industry is searching for ways to include more diverse datasets.

Expanded offerings will increase Black representation in clinical trials, ensuring that new medicines are safe and effective for people of color.

Survey examines trial enrollment motivation among diverse populations.

Advancing responsible AI innovation to help resolve patient disparities.